BNTC

Benitec Biopharma Inc.

Price Chart

Latest Quote

$12.09

+0.29 (+2.46%)

Current Price

Previous Close	$11.80
Open	$12.09
Day High	$12.33
Day Low	$11.87
Volume	77,681

Fetched: 2026-06-18T18:56:36

Stock Information

Shares Outstanding	34.35M
Total Debt	$876K
Cash Equivalents	$184.76M
Net Income	$-41.54M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$415.34M
EPS (TTM)	$-0.93
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$197.45M
Income	$-41.54M
Book/sh	$5.34
Cash/sh	$5.38
Employees	19

Financial Ratios

Quick Ratio	56.43
Current Ratio	56.82
Debt/Eq	0.48

Returns & Margins

ROA	-19.93%
ROE	-29.58%

Ownership

Insider Ownership	2.70%
Institutional Ownership	98.25%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-1.28
P/B	2.27

Analyst Data

Recommendation	strong_buy
Target Price	$25.80

Technical Indicators

SMA20	$11.12
SMA50	$11.80
SMA200	$12.56
RSI	55.05
ATR	0.6667

Shares Float	17.87M
Short Float	12.01%
Short Ratio	26.01
Volatility	0.28
Rel Volume	0.91

Performance History

Week	+9.41%
Month	+12.78%
Quarter	+5.13%
6 Months	-2.58%
YTD	-3.93%
Year	-21.70%
3 Years	+209.21%
5 Years	-84.90%
10 Years	-96.46%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$12.09	77,681
2026-06-17	$11.80	152,200
2026-06-16	$11.10	86,900
2026-06-15	$11.33	83,000
2026-06-12	$11.18	73,900
2026-06-11	$11.05	189,200
2026-06-10	$10.39	71,300
2026-06-09	$10.81	92,100
2026-06-08	$10.50	68,600
2026-06-05	$10.55	42,200
2026-06-04	$11.05	44,900
2026-06-03	$10.40	88,600
2026-06-02	$10.58	96,600
2026-06-01	$10.82	82,500
2026-05-29	$11.56	82,600
2026-05-28	$11.56	76,300
2026-05-27	$11.60	57,600
2026-05-26	$11.45	93,000
2026-05-22	$11.23	100,500
2026-05-21	$11.36	43,600
2026-05-20	$10.99	84,000
2026-05-19	$10.72	88,200
2026-05-18	$10.89	64,200

About Benitec Biopharma Inc.

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

📰 Latest News

Here's Why We're Not At All Concerned With Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Situation

Simply Wall St. • 2026-02-14T13:27:06Z

Does Benitec Biopharma (BNTC) Have the Potential to Rally 83.87% as Wall Street Analysts Expect?

Zacks • 2025-12-24T14:55:02Z

Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know

Zacks • 2025-12-05T14:55:03Z

Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC)

Zacks • 2025-12-03T14:35:02Z

Citizens Lifts Benitec Biopharma Inc. (BNTC) Price Target on Topline Results for Oculopharyngeal Muscular Dystrophy Treatment

Insider Monkey • 2025-11-18T11:16:56Z

Hedge funds investors have a lot riding on Benitec Biopharma Inc. (NASDAQ:BNTC) with 37% ownership

Simply Wall St. • 2025-11-18T10:27:58Z

Big Insider Purchases by Carl Icahn, Mario Gabelli, and Others

24/7 Wall St. • 2025-11-12T14:45:23Z

We're Interested To See How Benitec Biopharma (NASDAQ:BNTC) Uses Its Cash Hoard To Grow

Simply Wall St. • 2025-08-17T12:02:18Z

Is McKesson (MCK) Stock Outpacing Its Medical Peers This Year?

Zacks • 2025-06-20T13:40:06Z

Period:

Income Statement (Annual)

Metric	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Revenue
Total Revenue	$0	$0	$75,000	$73,000
Operating Revenue	$0	$0	$75,000	$73,000
Reconciled Cost Of Revenue	-	-	$0	$9,000
Cost Of Revenue	-	-	$0	$9,000
Expenses
Total Expenses	$41,765,000	$22,490,000	$19,156,000	$17,927,000
Other Income Expense	$562,000	$-165,000	$-448,000	$-322,000
Other Non Operating Income Expenses	$633,000	$-204,000	$-30,000	$-79,000
Net Non Operating Interest Income Expense	$3,286,000	$904,000	$-33,000	$-32,000
Total Other Finance Cost	$-3,286,000	$-904,000	$33,000	-
Operating Expense	$41,765,000	$22,490,000	$19,156,000	$17,918,000
General And Administrative Expense	$23,433,000	$6,989,000	$6,382,000	$6,646,000
Other Operating Expenses	-	$-108,000	-	$9,000
Interest Expense	-	-	$33,000	$32,000
Interest Expense Non Operating	-	-	$33,000	$32,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-37,917,000	$-21,751,000	$-19,562,000	$-18,208,000
Net Interest Income	$3,286,000	$904,000	$-33,000	$-32,000
Normalized Income	$-37,846,000	$-21,790,000	$-19,144,000	$-17,965,000
Net Income From Continuing And Discontinued Operation	$-37,917,000	$-21,751,000	$-19,562,000	$-18,208,000
Total Operating Income As Reported	$-41,765,000	$-22,490,000	$-19,081,000	$-17,854,000
Net Income Common Stockholders	$-37,917,000	$-22,370,000	$-19,562,000	$-18,208,000
Net Income	$-37,917,000	$-21,751,000	$-19,562,000	$-18,208,000
Net Income Including Noncontrolling Interests	$-37,917,000	$-21,751,000	$-19,562,000	$-18,208,000
Net Income Continuous Operations	$-37,917,000	$-21,751,000	$-19,562,000	$-18,208,000
Pretax Income	$-37,917,000	$-21,751,000	$-19,562,000	$-18,208,000
Special Income Charges	$764,000	$0	-	-
Operating Income	$-41,765,000	$-22,490,000	$-19,081,000	$-17,854,000
Gross Profit	-	-	$75,000	$64,000
Interest Income	-	-	-	-
Interest Income Non Operating	-	-	-	-
Per Share
Diluted EPS	$-1.05	$-1.22	$-14.12	$-37.91
Basic EPS	$-1.05	$-1.22	$-14.12	$-37.91
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-41,298,000	$-22,186,000	$-18,282,000	$-17,541,000
Total Unusual Items	$-71,000	$39,000	$-418,000	$-243,000
Total Unusual Items Excluding Goodwill	$-71,000	$39,000	$-418,000	$-243,000
Reconciled Depreciation	$396,000	$343,000	$381,000	$392,000
EBITDA (Bullshit earnings)	$-41,369,000	$-22,147,000	$-18,700,000	$-17,784,000
EBIT	$-41,765,000	$-22,490,000	$-19,081,000	$-18,176,000
Diluted Average Shares	$36,209,271	$18,364,386	$1,385,818	$480,687
Basic Average Shares	$36,209,271	$18,364,386	$1,385,818	$480,687
Diluted NI Availto Com Stockholders	$-37,917,000	$-22,370,000	$-19,562,000	$-18,208,000
Otherunder Preferred Stock Dividend	$0	$619,000	$0	-
Other Special Charges	$-764,000	-	-	-
Gain On Sale Of Security	$-71,000	$39,000	$-418,000	$-243,000
Research And Development	$18,332,000	$15,609,000	$12,774,000	$11,272,000
Selling General And Administration	$23,433,000	$6,989,000	$6,382,000	$6,646,000
Other Gand A	$23,433,000	$6,989,000	$6,382,000	$6,646,000
Salaries And Wages	-	-	$291,000	$613,000

Fetched: 2026-06-16

Balance Sheet (Annual)

Metric	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Assets
Net Tangible Assets	$97,295,000	$47,248,000	$202,000	$2,882,000
Total Assets	$99,592,000	$52,210,000	$4,464,000	$5,973,000
Total Non Current Assets	$1,074,000	$536,000	$735,000	$1,153,000
Non Current Prepaid Assets	$83,000	$87,000	$25,000	$25,000
Current Assets	$98,518,000	$51,674,000	$3,729,000	$4,820,000
Other Current Assets	$628,000	$516,000	$1,184,000	$741,000
Restricted Cash	$113,000	$63,000	$13,000	$14,000
Receivables	$33,000	$229,000	$55,000	$3,000
Accounts Receivable	$33,000	$229,000	$55,000	$3,000
Cash Cash Equivalents And Short Term Investments	$97,744,000	$50,866,000	$2,477,000	$4,062,000
Cash And Cash Equivalents	$97,744,000	$50,866,000	$2,477,000	$4,062,000
Cash Financial	$97,744,000	$50,866,000	$2,477,000	$4,062,000
Other Non Current Assets	-	$62,000	$97,000	$135,000
Prepaid Assets	-	-	-	$741,000
Cash Equivalents	-	-	-	-
Debt
Total Debt	$849,000	$284,000	$559,000	$811,000
Long Term Debt And Capital Lease Obligation	$495,000	$0	$284,000	$559,000
Current Debt And Capital Lease Obligation	$354,000	$284,000	$275,000	$252,000
Liabilities
Total Liabilities Net Minority Interest	$2,297,000	$4,962,000	$4,262,000	$3,091,000
Total Non Current Liabilities Net Minority Interest	$495,000	$38,000	$284,000	$559,000
Current Liabilities	$1,802,000	$4,924,000	$3,978,000	$2,532,000
Payables And Accrued Expenses	$1,022,000	$4,165,000	$3,231,000	$1,880,000
Payables	$268,000	$1,489,000	$1,209,000	$493,000
Other Payable	$67,000	$138,000	$69,000	$71,000
Accounts Payable	$201,000	$1,351,000	$1,140,000	$422,000
Equity
Common Stock Equity	$97,295,000	$47,248,000	$202,000	$2,882,000
Total Equity Gross Minority Interest	$97,295,000	$47,248,000	$202,000	$2,882,000
Stockholders Equity	$97,295,000	$47,248,000	$202,000	$2,882,000
Gains Losses Not Affecting Retained Earnings	$-839,000	$-892,000	$-830,000	$-1,245,000
Other Equity Adjustments	$-839,000	$-892,000	$-830,000	$-1,245,000
Retained Earnings	$-228,176,000	$-190,259,000	$-167,889,000	$-148,327,000
Other
Ordinary Shares Number	$26,250,469	$10,086,119	$1,645,950	$480,687
Share Issued	$26,250,469	$10,086,119	$1,645,950	$480,687
Tangible Book Value	$97,295,000	$47,248,000	$202,000	$2,882,000
Invested Capital	$97,295,000	$47,248,000	$202,000	$2,882,000
Working Capital	$96,716,000	$46,750,000	$-249,000	$2,288,000
Capital Lease Obligations	$849,000	$284,000	$559,000	$811,000
Total Capitalization	$97,295,000	$47,248,000	$202,000	$2,882,000
Additional Paid In Capital	$326,308,000	$238,398,000	$168,921,000	$152,454,000
Capital Stock	$2,000	$1,000	$0	$0
Common Stock	$2,000	$1,000	$0	$0
Preferred Stock	$0	$0	-	-
Employee Benefits	$0	$38,000	-	-
Long Term Capital Lease Obligation	$495,000	$0	$284,000	$559,000
Current Capital Lease Obligation	$354,000	$284,000	$275,000	$252,000
Pensionand Other Post Retirement Benefit Plans Current	$426,000	$475,000	$472,000	$400,000
Current Accrued Expenses	$754,000	$2,676,000	$2,022,000	$1,387,000
Net PPE	$991,000	$449,000	$613,000	$993,000
Accumulated Depreciation	$-1,470,000	$-1,404,000	$-1,318,000	$-1,182,000
Gross PPE	$2,461,000	$1,853,000	$1,931,000	$2,175,000
Leases	$24,000	$24,000	$24,000	$24,000
Other Properties	$1,533,000	$1,521,000	$1,343,000	$1,343,000
Machinery Furniture Equipment	$44,000	$38,000	$38,000	$37,000
Buildings And Improvements	$860,000	$270,000	$526,000	$771,000
Properties	$0	$0	$0	$0
Long Term Provisions	-	$38,000	-	-

Fetched: 2026-06-16

Cash Flow Statement (Annual)

Metric	2025-06-30	2024-06-30	2023-06-30	2022-06-30
Free Cash Flow
Free Cash Flow	$-23,606,000	$-19,582,000	$-18,013,000	$-15,912,000
Operating Activities
Operating Cash Flow	$-23,588,000	$-19,403,000	$-18,012,000	$-15,899,000
Cash Flow From Continuing Operating Activities	$-23,588,000	$-19,403,000	$-18,012,000	$-15,899,000
Investing Activities
Capital Expenditure	$-18,000	$-179,000	$-1,000	$-13,000
Investing Cash Flow	$-18,000	$-179,000	$-1,000	$-13,000
Cash Flow From Continuing Investing Activities	$-18,000	$-179,000	$-1,000	$-13,000
Financing Activities
Issuance Of Capital Stock	$30,460,000	$70,883,000	$17,884,000	$0
Financing Cash Flow	$70,485,000	$68,029,000	$16,015,000	$0
Cash Flow From Continuing Financing Activities	$70,485,000	$68,029,000	$16,015,000	$0
Net Other Financing Charges	$-2,319,000	$-5,892,000	$-1,869,000	-
Net Common Stock Issuance	$30,460,000	$70,883,000	$17,884,000	$0
Common Stock Issuance	$30,460,000	$70,883,000	$17,884,000	$0
Other
End Cash Position	$97,857,000	$50,929,000	$2,490,000	$4,076,000
Beginning Cash Position	$50,929,000	$2,490,000	$4,076,000	$19,784,000
Effect Of Exchange Rate Changes	$49,000	$-8,000	$412,000	$204,000
Changes In Cash	$46,879,000	$48,447,000	$-1,998,000	$-15,912,000
Proceeds From Stock Option Exercised	$42,344,000	$3,038,000	-	-
Net PPE Purchase And Sale	$-18,000	$-179,000	$-1,000	$-13,000
Purchase Of PPE	$-18,000	$-179,000	$-1,000	$-13,000
Change In Working Capital	$-2,729,000	$1,174,000	$714,000	$1,037,000
Change In Other Current Liabilities	$-356,000	$-275,000	$-252,000	$-196,000
Change In Payables And Accrued Expense	$-2,459,000	$980,000	$1,430,000	$1,090,000
Change In Accrued Expense	$-81,000	$39,000	$73,000	-
Change In Payable	$-2,378,000	$941,000	$1,357,000	$1,090,000
Change In Prepaid Assets	$-111,000	$645,000	$-414,000	$62,000
Change In Receivables	$197,000	$-176,000	$-50,000	$1,000
Other Non Cash Items	$-764,000	-	-	-
Stock Based Compensation	$17,426,000	$830,000	$452,000	$870,000
Unrealized Gain Loss On Investment Securities	$0	$1,000	$3,000	$10,000
Depreciation Amortization Depletion	$396,000	$343,000	$381,000	$392,000
Depreciation And Amortization	$396,000	$343,000	$381,000	$392,000
Depreciation	$396,000	$343,000	$381,000	$392,000
Net Income From Continuing Operations	$-37,917,000	$-21,751,000	$-19,562,000	$-18,208,000
Change In Other Working Capital	-	-	$73,000	$80,000
Sale Of PPE	-	-	-	-
Gain Loss On Sale Of PPE	-	-	-	-

Fetched: 2026-06-16